Following on from BPP’s involvement in several projects at their Marcy l’Etoile facility Genzyme announced the construction of a new biomanufacturing plant in Lyon, France. The Marcy l’Etoile plant was designed to handle the exclusive production of two drugs in the field of transplantation, but had become too small for the production volume that is required.
The new biomanufacturing plant would replace the Marcy l’Etoile plant, having more than twice the production capacity for Thymoglobulin (a polyclonal antibody). Genzyme has a resolve and commitment to innovation and sustainable development. This new facility has an attractive and contemporary architectural design and uses state-of-the-art green technology to provide a comfortable atmosphere while reducing the impact the plant has on the environment. The plant is one of the first manufacturing sites in France to gain HEQ certification, which is similar to the certification provided by the US Green Building Council through its LEED (Leadership in Energy and Environmental Design) green-building rating system.